Cargando…

Altered Prostanoid Metabolism Contributes to Impaired Angiogenesis in Persistent Pulmonary Hypertension of the Newborn

BACKGROUND: PPHN is associated with decreased lung angiogenesis and impaired pulmonary vasodilatation at birth. Prostanoids are important modulators of vascular tone and angiogenesis. We hypothesized that altered levels of prostacyclin (PGI(2)), a potent vasodilator, and thromboxane (TXA(2)), a vaso...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mahajan, Chaitali N., Afolayan, Adeleye J., Eis, Annie, Teng, Ru-Jeng, Konduri, Girija G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2014
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4346417/ https://www.ncbi.nlm.nih.gov/pubmed/25521916 http://dx.doi.org/10.1038/pr.2014.209

Ejemplares similares

Altered hypoxia‐inducible factor–1α (HIF‐1α) signaling contributes to impaired angiogenesis in fetal lambs with persistent pulmonary hypertension of the newborn (PPHN)
por: Makker, Kartikeya, et al.
Publicado: (2019)

Antenatal betamethasone improves postnatal transition in late preterm lambs with persistent pulmonary hypertension of the newborn
por: Konduri, Girija G., et al.
Publicado: (2013)

Fetal pulmonary hypertension: dysregulated microRNA-34c-Notch1 axis contributes to impaired angiogenesis in an ovine model
por: Mukherjee, Devashis, et al.
Publicado: (2023)

Role of endoplasmic reticulum stress in impaired neonatal lung growth and bronchopulmonary dysplasia
por: Pritchard, Kirkwood A., et al.
Publicado: (2022)

Contribution of prostanoid FP receptor and prostaglandins in transient inflammatory ocular hypertension
por: Yamagishi-Kimura, Reiko, et al.
Publicado: (2018)

Prostanoid therapies in the management of pulmonary arterial hypertension
por: LeVarge, Barbara L
Publicado: (2015)

Decreased AMP‐activated protein kinase (AMPK) function and protective effect of metformin in neonatal rat pups exposed to hyperoxia lung injury
por: Yadav, Abha, et al.
Publicado: (2020)

Complex Role for E‐Prostanoid 4 Receptors in Hypertension
por: Herrera, Marcela, et al.
Publicado: (2019)

Transitioning Between Prostanoid Therapies in Pulmonary Arterial Hypertension
por: Pan, Irene Z., et al.
Publicado: (2020)

OPTICAL IMAGING OF LIPOPOLYSACCHARIDE-INDUCED OXIDATIVE STRESS IN ACUTE LUNG INJURY FROM HYPEROXIA AND SEPSIS
por: SEPEHR, REYHANEH, et al.
Publicado: (2013)

Impact of Parenteral Prostanoids in Pulmonary Arterial Hypertension: The Relevance of Timing
por: Papa, Silvia, et al.
Publicado: (2023)

Caffeine Ameliorates Hyperoxia-Induced Lung Injury by Protecting GCH1 Function in Neonatal Rat Pups
por: Jing, Xigang, et al.
Publicado: (2017)

Persistent pulmonary hypertension of the newborn
por: Sharma, Vinay, et al.
Publicado: (2015)

Persistent Pulmonary Hypertension in the Newborn
por: Mathew, Bobby, et al.
Publicado: (2017)

Physiology and pathophysiology of prostanoid receptors
por: Narumiya, Shuh
Publicado: (2007)

Management of acute subdural hematoma in a patient with portopulmonary hypertension on prostanoid therapy
por: Rammo, Richard, et al.
Publicado: (2017)

Parenteral prostanoids for severe Group 3 pulmonary hypertension with right ventricular dysfunction
por: Hinkamp, Colin A., et al.
Publicado: (2021)

Role of prostanoids, nitric oxide and endothelin pathways in pulmonary hypertension due to COPD
por: Alqarni, Abdullah A., et al.
Publicado: (2023)

Prostanoid Receptors in the Human Vascular Wall
por: Norel, Xavier
Publicado: (2007)

Prostanoid Metabolites as Biomarkers in Human Disease
por: Idborg, Helena, et al.
Publicado: (2022)

The Link between Prostanoids and Cardiovascular Diseases
por: Beccacece, Livia, et al.
Publicado: (2023)

Parenteral Prostanoids in Pediatric Pulmonary Arterial Hypertension: Start Early, Dose High, Combine
por: Douwes, Johannes M., et al.
Publicado: (2022)

Transitioning Stable Patients with Pulmonary Arterial Hypertension from Parenteral Prostanoids to Oral Selexipag
por: Hinkamp, Colin, et al.
Publicado: (2022)

Altered Prostanoid Signaling Contributes to Increased Skin Tumorigenesis in Tpl2 Knockout Mice
por: DeCicco-Skinner, Kathleen L., et al.
Publicado: (2013)

Contribution of prostanoid signaling to the evolution of spreading depolarization and the associated cerebral blood flow response
por: Varga, Dániel Péter, et al.
Publicado: (2016)

Patient Characteristics in Persistent Pulmonary Hypertension of the Newborn
por: Roofthooft, M. T. R., et al.
Publicado: (2011)

Risk factors for persistent pulmonary hypertension of the newborn
por: Delaney, Cassidy, et al.
Publicado: (2012)

Altered metabolites in newborns with persistent pulmonary hypertension
por: Steurer, Martina A., et al.
Publicado: (2018)

Effect of Prostanoids on Human Platelet Function: An Overview
por: Braune, Steffen, et al.
Publicado: (2020)

Crotoxin-Induced Mice Lung Impairment: Role of Nicotinic Acetylcholine Receptors and COX-Derived Prostanoids
por: Sartim, Marco Aurelio, et al.
Publicado: (2020)

Postnatal causes and severity of persistent pulmonary Hypertension of Newborn
por: Arshad, Muhammad Sohail, et al.
Publicado: (2021)

Diastolic ventricular function in persistent pulmonary hypertension of the newborn
por: Le Duc, Kévin, et al.
Publicado: (2023)

Factors leading to supranormal cardiac index in pediatric pulmonary hypertension patients treated with parenteral prostanoid therapy
por: Miles, Kimberley G., et al.
Publicado: (2023)

Outcomes of Infants with Hypoxic Ischemic Encephalopathy and Persistent Pulmonary Hypertension of the Newborn: Results from Three NICHD Studies
por: Agarwal, Prashant, et al.
Publicado: (2021)

Maternal tobacco smoke exposure and persistent pulmonary hypertension of the newborn.
por: Bearer, C, et al.
Publicado: (1997)

Risk factors and mortality among newborns with persistent pulmonary hypertension
por: Razzaq, Athar, et al.
Publicado: (2013)

The Use of Supplemental Hydrocortisone in the Management of Persistent Pulmonary Hypertension of the Newborn
por: Aleem, Samia, et al.
Publicado: (2021)

Long‐term safety of a structured transition protocol from parenteral prostanoids to selexipag in pulmonary arterial hypertension
por: Tamura, Yuichi, et al.
Publicado: (2022)

The Immunobiology of Prostanoid Receptor Signaling in Connecting Innate and Adaptive Immunity
por: Harizi, Hedi
Publicado: (2013)

Prostanoids and Resolution of Inflammation – Beyond the Lipid-Mediator Class Switch
por: Schmid, Tobias, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_e2401m3l16hupvbdia4scg8v4k